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the initial laboratory evaluation revealed an erythrocyte 
sedimentation rate (ESR) of 61 mm/h (normal value <10) 
and a serum C-reactive protein (CRP) level of 12 mg/L 
(normal value <5). Rheumatoid factor was 184 uI/mL 
(normal range <20), and serum angiotensin-converting 
enzyme (SaCE) was 65 u/I (normal value 8–52 u/L). 
Full blood count and blood chemistry were all within the 
normal range. Immunoglobulin G levels were 21.3 g/L 
(normal values 7.0–16.0 g/L); kappa light chain 18.58 g/L 
(6.66–14.65 g/L); and lambda light chain 7.43 g/L (2.99–
6.99 g/L), with no detection of monoclonal component. 
Purified protein derivative test result was negative (an indu-
ration <5 mm).
her chest radiograph (Fig. 1a) and high-resolution com-
puted tomography (hRCt) (Fig. 2a) showed hilar and 
mediastinal lymphadenopathy and multiple small pulmo-
nary nodules. Lung function tests and carbon monoxide 
diffusing capacity were normal. Bronchoalveolar lavage 
demonstrated an increase in CD4+/CD8+ t cell ratio 
(12.4). mycobacterial and fungal cultures were negative. 
to investigate the pulmonary nodules, a mediastinoscopy-
directed biopsy was performed. the histological exam 
revealed multiple noncaseating granulomas. 
the diagnosis of sarcoidosis (stage II) was established 
based on the clinical, imaging, and pathological find-
ings. the patient was diagnosed with coexisting pSS and 
sarcoidosis.
Because the respiratory symptoms and fatigue worsened 
over time, the patient was empirically treated with pred-
nisolone 0.3 mg/kg/day for 6 weeks, with a slow taper-
ing over 6 months, associated with calcium supplementa-
tion and alendronic acid/colecalciferol (70 mg/5,600 uI, 
weekly) [1].
Gradually, all the symptoms improved, and 1 year later, 
the patient denied any respiratory or systemic symptoms. 
Abstract herein, we describe a 44-year-old female diag-
nosed with histologically proven coexistence of primary 
Sjögren’s syndrome and sarcoidosis with pulmonary and 
muscular involvement. the differential diagnosis may be 
difficult, but this is not an exceptional case, which high-
lights the need to critically revise the consideration of sar-
coidosis as an exclusion for primary Sjögren’s syndrome, 
as established in current classification criteria.
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Case report
a 44-year-old Caucasian female was referred to our Depart-
ment due to a 2-week history of dyspnea, persistent dry cough, 
arthralgia, and fatigue. Four years previously, primary Sjögren 
syndrome (pSS) had been diagnosed on the presence of sicca 
symptoms associated with SSa and SSB auto-antibodies, and 
a salivary gland biopsy demonstrating lymphocytic infiltrates 
(Chisholm-mason classification grade IV). She had been suc-
cessfully treated with hydroxychloroquine 400 mg/day and an 
ophthalmic emulsion. her family and occupational and envi-
ronmental histories were not contributory.
Physical examination showed normal vital signs, and 
cardiovascular, pulmonary, and musculoskeletal clinical 
examinations were unremarkable. no peripheral adenopa-
thies were noted.
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Repeat hRCt of the chest demonstrated complete resolu-
tion of hilar and mediastinal lymphadenopathy (Fig. 1b).
two years after the diagnosis of pulmonary sarcoidosis, 
the patient presented with acute inflammatory myopathy. 
She described an insidious proximal symmetrical weak-
ness of the upper limbs. Laboratory studies showed serum 
creatine kinase of 562 u/L (normal value <145 u/L) and 
raised aCE to 115 u/L. Electromyographic examination 
was considered normal. the magnetic resonance imaging 
of both arms showed features suggesting myositis (Fig. 3). 
Pathological examination of a biopsy of the deltoid mus-
cle revealed epithelioid granulomas, consistent with granu-
lomatous myositis (Fig. 4).
the patient was treated with prednisolone (1 mg/kg/
day). at present, 6 months after the diagnosis of granu-
lomatous myositis, the patient is still on prednisolone 
(0.1 mg/kg/day), which has achieved improvement on the 
muscular weakness and normalization of serum creatine 
kinase levels and aCE activity.
Discussion
the most recent classification criteria for pSS exclude 
this diagnosis in the presence of sarcoidosis [2]. this 
exclusion criterion was retained from the previous 
american-European Consensus Criteria from 2002 [3]. 
If such classification criteria were taken as “the truth” in 
clinical practice, sarcoidosis and pSS would be regarded as 
mutually exclusive conditions and their coexistence regu-
lated as “impossible” or at least “unlawful.” however, the 
prevalence of sarcoidosis in large series of patients with 
pSS ranges from 1 to 2 % [4–6]. although classification 
criteria are not to be taken as diagnostic criteria, they are 
bound to affect clinicians’ decisions and perceptions in 
clinical practice and induce diagnostic error or suboptimal 
management. the risk of circularity in the establishment of 
classification criteria also is a cause of concern: “Virtual 
reality” becomes modeled by factors used in its definition.
Sarcoidosis and pSS share pathogenic, immunogenetic, 
and clinical features. Both chronic inflammatory conditions 
of unknown origin are characterized by an intense cellular 
immune infiltrate at disease sites, predominantly composed 
of t lymphocytes [4, 5]. the similarity of the underly-
ing immunopathogenetic mechanisms has been argued as 
an explanation for the coexistence of both diseases. Other 
authors suggest the immunological derangement caused by 
one disorder may result in the other, and a third perspective 
suggests that this is a mere coincidence. the first hypoth-
esis is supported by findings in lung biopsy specimens from 
10 patients with SS [7]. there were significant elevations 
in CD4-positive lymphocytes in the bronchial mucosa, an 
Fig. 1  a at admission to rheu-
matology: bilateral hilar and 
right paratracheal lymphade-
nopathy, with right paratracheal 
enlargement. b Six months 
later: resolution of lymph node 
enlargement
Fig. 2  a Contrast-enhanced 
axial chest hRCt image show-
ing bilateral multiple micro-
nodular lesions; b mediastinal 
window: hilar and subcarinal 
lymphadenopathy
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abnormality that is also described in sarcoidosis. In addi-
tion, the hLa-DR3 phenotype is associated with pSS and 
with a subgroup of patients with sarcoidosis [8].
the coexistence of the two conditions may be a cause of 
concern for the clinician faced with this challenging clini-
cal scenario. Differentiating between pSS and sarcoidosis 
can raise difficulties when the symptoms are common to 
both conditions, as in the case of lung and exocrine gland 
involvement. the occurrence of features more typical of 
sarcoidosis, such as muscle involvement in the current 
case, facilitates the differential diagnosis.
to our knowledge, reports of a coexistence of both con-
ditions with histological proof of sarcoidosis are relatively 
scarce [4–7]. Our case underlines how important pathology 
can be to establish the true coincidence of sarcoidosis with 
pSS.
With this case, the authors wish to highlight two main 
points.
•	 Sarcoidosis should be considered in the differential 
diagnosis for lung and exocrine gland involvement in 
pSS, thus requiring a complete workout including tissue 
biopsy where appropriate.
In a patient with pSS, the differential diagnosis of dysp-
nea and cough includes xerotrachea, pulmonary vascu-
lar disease, and interstitial lung diseases that may present 
with sicca symptoms or salivary gland involvement (e.g., 
sarcoidosis, IgG4-related systemic disease) [9–11]. Sar-
coidosis may also present with lacrimal and salivary gland 
involvement, as well as diffuse parenchymal lung disease.
the histological exam distinguishes the two conditions, 
since noncaseating granulomas are present in sarcoidosis, 
while lung involvement by pSS is characterized by lym-
phocytic interstitial pneumonitis. the correct diagnosis has 
important therapeutic and prognostic implications. Lung 
sarcoidosis frequently resolves spontaneously, whereas 
lymphocytic interstitial pneumonitis frequently requires 
immunosuppressive treatment beyond glucocorticoids.
In a literature review published in 2004, Ramon-Casals 
et al. [6] identified 53 case reports of patients with sus-
pected coexistence of Sjögren syndrome and sarcoidosis, 
submitted to definitive histological investigation. true coex-
istence of these conditions was confirmed in 28 patients, by 
the demonstration of histological features specific to each 
disease: focal sialadenitis in the exocrine glands and non-
caseating granulomas in the exocrine glands or in other 
tissues. In the remaining 25 cases, sarcoidosis mimicked 
Sjögren’s syndrome [6]. Overall, noncaseating granulomas 
were found in extraglandular tissues in 45 of the 53 patients 
(76 %), predominantly in the lung (24–53 %) and in hilar 
and/or mediastinal lymph nodes (7–16 %). Biopsies of the 
exocrine glands performed in all 53 patients only revealed 
noncaseating granulomas in 22 (42 %). Focal sialadenitis 
coexisted with noncaseating granulomas in only six cases. 
In this review, the american-European Consensus Criteria 
Fig. 3  mRI images (coronal StIR) showing abnormal symmetrical 
signal with a moderate intensity, with a major relevance in biceps (red 
arrowhead), triceps (yellow arrowhead), and proximal portion of the 
deltoids (green arrowhead) suggesting edema and myositis
Fig. 4  histological aspect of the muscle biopsy, showing the presence 
of an endomysial lymphocytic infiltrates and an epithelioid noncase-
ating granuloma between muscle fibers. (h and E, ×200, paraffin). 
Courtesy of Dr. Olinda Rebelo (neuropathology Laboratory, neurol-
ogy Department, Centro hospitalar e universitário de Coimbra)
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for pSS [3] retained a high sensitivity and specificity in the 
presence of sarcoidosis.
as in our case, in patients first diagnosed with pSS, the 
presence of clinical features such as hilar and mediastinal 
adenopathies, uveitis, or hypercalcemia should raise the 
possibility of coexisting sarcoidosis. minor salivary gland 
biopsies, usually included in the workout for pSS, may 
show noncaseating granulomas in 38–58 % of the patients 
with sarcoidosis [12, 13]. therefore, the clinician needs to 
consider other tissues when these biopsies are negative.
In patients first diagnosed with sarcoidosis, especially 
when disseminated outside the lungs, the presence of anti-
nuclear antibodies, rheumatoid factor, and/or anti-Ro/La 
should alert to the possible coexistence of pSS. If the case 
remains unclear on clinical and immunological grounds, 
biopsies should be performed, including the minor salivary 
glands.
•	 When pSS coexists with sarcoidosis, sarcoid myopathy 
should be considered in the differential diagnosis for 
muscular involvement, thus requiring a complete work-
out including muscle biopsy.
In the reported cases of sarcoidosis coexisting with pSS, 
a higher prevalence of extrapulmonary sarcoidosis seems 
to occur [6]. muscular involvement is present in 50–80 % 
of individuals with sarcoidosis but is rarely (0.5–2.5 %) 
symptomatic. the finding of granulomatous myositis is 
highly suggestive of sarcoid myopathy. however, this is not 
a common finding: In a literature review of 26 patients with 
pSS and coexisting sarcoidosis, only one patient had sar-
coid involvement of the muscles [14, 15].
In conclusion, the available evidence suggests that the 
association between pSS and sarcoidosis may be more than 
casual. the growing number of reported cases suggests that 
the exclusion of pSS in the presence of sarcoidosis should 
be reconsidered. Of note, the coexistence of the two dis-
eases seems to be related to a higher frequency of extrapul-
monary involvement of sarcoidosis.
Clinicians should be aware of and explore the possibility 
of coexistence of both entities. a detailed clinical history 
(enquiring for systemic and respiratory symptoms, uveitis, 
and arthritis), the evaluation of aCE, calcium levels, and 
immunological profile, together with the tissue biopsy, are 
pivotal to this end and to the optimal treatment approach. In 
the presence of findings suggestive of sarcoidosis, the clini-
cian needs to be ready to extend histological examination 
beyond the exocrine glands.
Classification criteria should still be applied, but sar-
coidosis should not be taken as an exclusion criterium 
for the diagnosis of pSS in clinical practice. the persis-
tence of this exclusion in classification criteria needs to be 
reconsidered.
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